Comprehensive NeuroAIDS Core Center

综合神经艾滋病核心中心

• 批准号: 8477298
• 负责人: Kamel Khalili
• 金额: $ 155.5万
• 依托单位: TEMPLE UNIV OF THE COMMONWEALTH
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-05 至 2016-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8477298
• 关键词: AIDS neuropathy; Acquired Immunodeficiency Syndrome; Aftercare; Animal Model; Animals; Area; Basic Science; Behavior Disorders; Behavioral; Biological Markers; Caring; Cell Culture Techniques; Central Nervous System Diseases; Clinic; Clinical; Clinical Investigator; Clinical Sciences; Communication; Development; Diagnostic; Discipline; Effectiveness; Equation; Evaluation; Experimental Animal Model; Feasibility Studies; Fostering; Funding; Gene Expression; Government; HIV; HIV-1; Individual; Infection; Inpatients; Institution; Investigation; Laboratories; Laboratory Finding; Mammalian Cell; Medical; Medicine; Mental Health; Mental disorders; Mentors; Mentorship; Microbiology; Mission; Modality; Molecular; Molecular Biology; Molecular Medicine; Neurocognitive; Neurodegenerative Disorders; Neurologic; Neurologic Dysfunctions; Neurology; Neurosciences; Neurovirology; Patients; Pennsylvania; Philadelphia; Physicians; Pilot Projects; Proteomics; Public Health; Recruitment Activity; Research; Research Infrastructure; Research Personnel; Research Support; Rest; Scientist; Seeds; Services; Structure; Therapeutic; Therapeutic Agents; Time; Training; Translational Research; United States National Institutes of Health; Universities; University Hospitals; Validation; Virus; base; in vivo; innovation; interdisciplinary approach; medical schools; multidisciplinary; nervous system disorder; neurobehavioral disorder; neuropathology; neuropsychiatry; programs; virology

This revised application seeks support to establish a Comprehensive NeuroAIDS Core Center (CNACC) at the Temple University School of Medicine in order to bring highly needed infrastructure for basic scientists and clinicians involved in HIV-1/AIDS research and neurological, neurodegenerative, and neurobehavioral disorders. The central theme of CNACC is structured based on our hypothesis that understanding the mechanisms of HIV-1/CNS interactions at the molecular, cellular, and experimental animal model levels and bidirectional communication of laboratory findings and clinical observations to validate basic science discoveries are prerequisites for the development of effective, safe, and reliable approaches for early diagnostics and therapeutics for AIDS-associated neurological dysfunctions. The CNACC will provide unprecedented infrastructure to a large group of neuroAIDS investigators who plan to pursue their objectives using multidisciplinary approaches in cell culture, small animal models, and in the clinical setting for assessing gene expression and biomarker identification at the cellular and molecular levels. Further, through the Developmental Core, the CNACC will provide a unique opportunity for training and mentoring of junior and clinical investigators and attract and develop physician scientists in the field of neuroAIDS. Through CNACC, we will provide start-up funds for new and innovative pilot projects of newly recruited, independent investigators and will support feasibility studies for more established neuroAIDS investigators. The funding through this center will create a unique infrastructure that will serve to enhance and extend the effectiveness of ongoing HIV-1 investigations and promote translational research in neuroAIDS at Temple and other medical institutions in the greater Philadelphia area that are involved in basic science and clinical AIDS research. With its comprehensive structural organization encompassing broadly based cores ranging from molecular biology to experimental animals to the clinical arena directed by skilled and highly competent investigators from various disciplines, CNACC will support research in a variety of areas such as virology, basic and behavioral neuroscience, and clinical science, all of which are aimed toward the discovery of better diagnostics and effective therapeutic agents toward AIDS/CNS disorders.

这份修订后的申请寻求在天普大学医学院建立一个综合神经艾滋病核心中心（CNACC）的支持，以便为参与HIV-1/艾滋病研究以及神经、神经退行性和神经行为障碍的基础科学家和临床医生提供急需的基础设施。CNACC的中心主题是基于我们的假设，即理解HIV-1/CNS在分子、细胞和实验动物模型水平上的相互作用机制，以及实验室发现和临床观察的双向交流，以验证基础科学发现，是开发有效、安全、可靠的艾滋病相关神经功能障碍早期诊断和治疗方法的先决条件。CNACC将为一大群神经艾滋病研究者提供前所未有的基础设施，他们计划在细胞培养、小动物模型和临床环境中使用多学科方法来评估基因表达和细胞和分子水平的生物标志物鉴定，以追求他们的目标。此外，通过发展核心，CNACC将为初级和临床研究人员提供培训和指导的独特机会，并吸引和发展神经艾滋病领域的内科科学家。通过CNACC，我们将为新招募的独立研究者的新的和创新的试点项目提供启动资金，并将支持更多成熟的神经艾滋病研究者的可行性研究。通过该中心获得的资金将创建一个独特的基础设施，用于加强和扩大正在进行的HIV-1研究的有效性，并促进坦普尔和大费城地区其他参与基础科学和临床艾滋病研究的医疗机构在神经艾滋病方面的转化研究。CNACC将支持病毒学、基础神经科学和行为神经科学、临床科学等多个领域的研究，旨在发现针对艾滋病/中枢神经系统疾病的更好的诊断和有效的治疗药物。CNACC的综合结构组织包括分子生物学、实验动物和临床领域的广泛核心。